3 results
The primary objective of the VertiGO! trial is to assess the feasibility of restoring vestibular function by making use of prolonged VI stimulation. This will be done using a combined VI and CI device: The CVI. To achieve this objective, patients…
Primary objective:•To establish the recommended phase 2 dose of Vyxeos®/CPX-351 in combination with clofarabine in children with relapsed/refractory AML Secondary objectives:•To determine the safety and tolerability of this combination•To determine…
Primary Objective:- Achieving an event-free survival, which is not inferior to the ML-DS 2006 trial (87±3%)Secondary Objective(s):- Reduction of toxicity: severe adverse events (CTCAE v4.0 grade III or higher)- Evaluation of response- Identification…